Free Trial

Ascendis Pharma A/S (ASND) Competitors

Ascendis Pharma A/S logo
$194.62 -0.96 (-0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$194.50 -0.12 (-0.06%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ASND vs. TAK, ARGX, ONC, INSM, BNTX, TEVA, SMMT, GMAB, VTRS, and RDY

Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

Ascendis Pharma A/S vs. Its Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.

Ascendis Pharma A/S presently has a consensus price target of $244.36, suggesting a potential upside of 25.56%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
3.00
Takeda Pharmaceutical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 10 articles in the media. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Takeda Pharmaceutical's score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Takeda Pharmaceutical
2 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Takeda Pharmaceutical has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$490.75M24.28-$409.12M-$5.16-37.72
Takeda Pharmaceutical$30.09B1.59$712.33M$0.3050.27

Takeda Pharmaceutical has a net margin of 3.20% compared to Ascendis Pharma A/S's net margin of -54.94%. Takeda Pharmaceutical's return on equity of 10.50% beat Ascendis Pharma A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S-54.94% N/A -24.31%
Takeda Pharmaceutical 3.20%10.50%5.10%

Summary

Takeda Pharmaceutical beats Ascendis Pharma A/S on 8 of the 15 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASND vs. The Competition

MetricAscendis Pharma A/SMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.91B$3.11B$5.75B$10.28B
Dividend YieldN/A2.32%5.72%4.60%
P/E Ratio-37.7221.3674.9926.41
Price / Sales24.28240.89456.1088.49
Price / CashN/A44.4425.8129.91
Price / Book-103.529.6413.256.28
Net Income-$409.12M-$53.20M$3.29B$270.38M
7 Day Performance-5.17%0.41%0.46%2.69%
1 Month Performance-1.87%4.23%4.59%5.98%
1 Year Performance63.24%9.41%73.41%25.93%

Ascendis Pharma A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASND
Ascendis Pharma A/S
3.1994 of 5 stars
$194.62
-0.5%
$244.36
+25.6%
+64.0%$11.91B$490.75M-37.721,017Positive News
TAK
Takeda Pharmaceutical
2.4572 of 5 stars
$15.27
-0.9%
N/A+2.8%$49.00B$30.09B50.8847,455High Trading Volume
ARGX
argenex
3.9706 of 5 stars
$768.00
+2.3%
$772.84
+0.6%
+40.6%$45.95B$2.25B39.381,599Analyst Downgrade
ONC
BeOne Medicines
1.6955 of 5 stars
$346.45
+1.4%
$330.89
-4.5%
N/A$37.46B$3.81B-200.2611,000Insider Trade
INSM
Insmed
3.3486 of 5 stars
$146.68
+1.1%
$139.86
-4.7%
+95.5%$30.67B$363.71M-25.691,271Positive News
BNTX
BioNTech
2.5214 of 5 stars
$102.66
-8.7%
$135.80
+32.3%
-21.6%$27.04B$2.98B-64.166,772High Trading Volume
TEVA
Teva Pharmaceutical Industries
2.9952 of 5 stars
$19.30
+1.8%
$24.71
+28.1%
+8.4%$21.73B$16.54B-120.6136,830
SMMT
Summit Therapeutics
3.0865 of 5 stars
$19.44
-25.2%
$33.79
+73.8%
-40.7%$19.30BN/A-19.25110Gap Down
High Trading Volume
GMAB
Genmab A/S
3.9454 of 5 stars
$27.54
flat
$37.60
+36.5%
+3.4%$17.67B$3.12B13.842,682Positive News
VTRS
Viatris
1.5976 of 5 stars
$10.48
-0.2%
$10.40
-0.8%
-14.6%$12.24B$14.74B-3.6132,000
RDY
Dr. Reddy's Laboratories
2.2893 of 5 stars
$14.27
-0.5%
$16.95
+18.8%
-8.9%$11.97B$3.81B21.6127,811News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:ASND) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners